Treatment of neuropathy
First Claim
Patent Images
1. A method of treating a patient suffering from neuropathy which comprises treating said patient with an effective amount of a cGMP PDE5 inhibitor, with the proviso that the inhibitor is not a:
- i) substituted 5-(3-pyridyl)pyrazolo[4,3-d]pyrimidin-7-one, ii) substituted 2-(3-pyridyl)-4a,5-dihydroimidazo[5, 1-f][1,2,4]triazin-4(3H)-one, or iii) substituted 2-phenylpurin-6-one or a substituted 2-(3-pyridyl)purin-6-one, for treating peripheral diabetic neuropathy.
2 Assignments
0 Petitions
Accused Products
Abstract
This invention relates to the use of cyclic guanosine 3′,5′-monophosphate phosphodiesterase type five (cGMP PDE5) inhibitors, including in particular the compound sildenafil, for the treatment of neuropathy, including in particular the treatment of diabetic neuropathy.
-
Citations
16 Claims
-
1. A method of treating a patient suffering from neuropathy which comprises treating said patient with an effective amount of a cGMP PDE5 inhibitor, with the proviso that the inhibitor is not a:
-
i) substituted 5-(3-pyridyl)pyrazolo[4,3-d]pyrimidin-7-one, ii) substituted 2-(3-pyridyl)-4a,5-dihydroimidazo[5, 1-f][1,2,4]triazin-4(3H)-one, or iii) substituted 2-phenylpurin-6-one or a substituted 2-(3-pyridyl)purin-6-one, for treating peripheral diabetic neuropathy. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8)
-
-
9. The use of a cGMP-PDE5 inhibitor for the manufacture of a medicament for the treatment of neuropathy, with the proviso that the inhibitor is not a:
-
i) substituted 5-(3-pyridyl)pyrazolo[4,3-d]pyrimidin-7-one, ii) substituted 2-(3-pyridyl)-4a, 5-dihydroimidazo[5, 1-f][1,2,4]triazin-4(3H)-one, or iii) substituted 2-phenylpurin-6-one or a substituted 2-(3-pyridyl)purin-6-one, for treating peripheral diabetic neuropathy. - View Dependent Claims (10, 11, 12, 13, 14, 15, 16)
-
Specification